<DOC>
	<DOCNO>NCT00002286</DOCNO>
	<brief_summary>To evaluate feasibility Retrovir ( AZT ) treatment psoriasis HIV antibody positive patient . Retrovir show effective treatment AIDS . In addition , administration AZT appear induced remission psoriasis one case study . In light AZT 's antiviral activity potential effectiveness agent treatment psoriasis , would likely treatment HIV positive , psoriatic patient whose disease progress quickly .</brief_summary>
	<brief_title>A Study Retrovir Treatment Psoriasis HIV-Positive Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Study participant must biopsyproven psoriasis 3 distinct psoriatic lesion . ( Biopsyproven Reiter 's syndrome patient 3 distinct cutaneous lesion may include . ) Documented HIV antibody ( federally license ELISA test ) positive patient . Prior Medication : Allowed : Zidovudine ( AZT ) . Exclusion Criteria Coexisting Condition : Patients follow exclude : Presence active opportunistic infection . Presence AIDSdefining neoplasm ( exclude Kaposi 's sarcoma ) central nervous system ( CNS ) lymphoma . Known hypersensitivity zidovudine ( AZT ) . Impaired renal function . Significant hepatic dysfunction . Concurrent Medication : Excluded : Topical steroid , anthralin , tar preparation . Etretinate , methotrexate , psoralen ultraviolet A ( PUVA ) therapy . Psoriatic treatment systemic agent topical steroid ( emollient use distal control lesion antipruritic shampoo admissible ) . Patients follow exclude : Presence active opportunistic infection . Presence AIDSdefining neoplasm ( exclude Kaposi 's sarcoma ) central nervous system ( CNS ) lymphoma . Known hypersensitivity zidovudine ( AZT ) . Impaired renal function . Significant hepatic dysfunction . Prior Medication : Excluded : Other antiretroviral agent ( e.g. , suramin , ribavirin , HPA23 , dideoxycytidine ) . Excluded within 2 week study entry : Topical steroid , anthralin , tar preparation . Any experimental therapy drug cause significant bone marrow suppression antifolates pyrimethamine . Cytolytic chemotherapy . Drugs cause significant nephrotoxicity hepatotoxicity . Rifampin rifampin derivative . Excluded within 4 week study entry : Etretinate , methotrexate , psoralen ultraviolet A ( PUVA ) therapy . Excluded within 8 week study entry : Immunomodulating agent , include steroid , interferon , Isoprinosine , interleukin 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 1989</verification_date>
	<keyword>Pilot Projects</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>